2022 METEORIC-HF Effect of Omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction Phase 3, double-blind, placebo-controlled randomized trial a Objective: To determine whether omecamtiv mecarbil, a novel direct myosin activator improves peak exercise capacity in patients with chronic HFrEF as compared to placebo 276 Inclusion criteria: Age >18 to 385 […]